has function has role immunizes against disease immunizes recipient cancer Homo sapiens recombinant vector vaccine therapeutic vaccine function vaccine in clinical trial role recombinant vector vaccine role ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine https://github.com/vaccineontology/VO/issues/171 cancer vaccine Jie Zheng Eliyas Asfaw Oliver He A cancer vaccine consisting of a replication-defective recombinant canarypox virus [ALVAC(2)] encoding the cancer-testis antigen NY-ESO and the TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; also called TRICOM), with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC(2)/NY-ESO (M)/TRICOM vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells, including bladder, breast, hepatocellular, melanoma, and prostate tumor cells. TRICOM may enhance antigen presentation and activate cytotoxic T-cells. In addition, ALVAC(2) encodes the vaccinia virus (vv) E3L ad K3L genes, which may potentiate the translation of the NY-ESO and TRICOM genes. Gene name: CD58 Ibrahim Seleznev 965 Gene name: NY-ESO-1 941 1485 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5268 3383 Gene name: CD80 5268 Gene name: ICAM1 NCT: https://clinicaltrials.gov/ct2/show/NCT01982487 therapeutic cancer vaccine